Opthea Limited Long-Term Debt | OPT

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Opthea Limited

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	84.2 K	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
84.2 K	84.2 K	84.2 K

Quarterly Long-Term Debt Opthea Limited

2025-Q2	2024-Q2	2023-Q2	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	82.5 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
82.5 K	82.5 K	82.5 K

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	13.2 M	-	-	-	Russia
Ayala Pharmaceuticals AYLA	1.33 M	-	-	$ 7.46 M	Israel
Amryt Pharma plc AMYT	4.05 M	-	-	$ 621 M	Britain
ASLAN Pharmaceuticals Limited ASLN	281 K	-	-14.27 %	$ 1.7 M	Singapore
Revolution Medicines RVMD	142 M	$ 207.32	0.24 %	$ 39.4 B	USA
Rhythm Pharmaceuticals RYTM	101 M	$ 101.8	0.08 %	$ 6.62 B	USA
Rezolute RZLT	983 K	$ 4.4	0.88 %	$ 334 M	USA
Sana Biotechnology SANA	63.9 M	$ 3.45	0.77 %	$ 874 M	USA
Seer SEER	21.1 M	$ 1.95	0.26 %	$ 108 M	USA
Precigen PGEN	93.2 M	$ 6.87	0.14 %	$ 2.15 B	USA
SIGA Technologies SIGA	200 K	$ 3.2	1.86 %	$ 229 M	USA
Syndax Pharmaceuticals SNDX	1.58 M	$ 19.94	0.05 %	$ 1.73 B	USA
Soligenix SNGX	244 K	$ 0.38	1.18 %	$ 1.97 M	USA
Spruce Biosciences SPRB	124 K	$ 59.09	2.0 %	$ 45.3 M	USA
Sarepta Therapeutics SRPT	829 M	$ 20.94	0.04 %	$ 2.1 B	USA
Stoke Therapeutics STOK	1.14 M	$ 30.05	0.81 %	$ 1.78 B	USA
Sutro Biopharma STRO	7.89 M	$ 19.1	0.34 %	$ 162 M	USA
Shattuck Labs STTK	1.58 M	$ 6.5	0.29 %	$ 452 M	USA
Supernus Pharmaceuticals SUPN	30.4 M	$ 42.43	0.23 %	$ 2.4 B	USA
Savara SVRA	29.9 M	$ 5.53	2.98 %	$ 1.23 B	USA
China SXT Pharmaceuticals SXTC	644 K	$ 2.24	0.45 %	$ 1.52 M	China
Takeda Pharmaceutical Company Limited TAK	4.51 T	$ 18.32	1.49 %	$ 28.9 B	Japan
Bio-Techne Corporation TECH	200 M	$ 72.31	0.01 %	$ 11.3 B	USA
Tenax Therapeutics TENX	64.2 K	$ 1.98	2.06 %	$ 77.7 M	USA
Teva Pharmaceutical Industries Limited TEVA	288 M	$ 36.76	1.21 %	$ 42.1 B	Israel
TG Therapeutics TGTX	246 M	$ 55.74	0.58 %	$ 8.04 B	USA
Trevi Therapeutics TRVI	446 K	$ 16.82	1.17 %	$ 2.27 B	USA
Taysha Gene Therapies TSHA	50.1 M	$ 5.48	0.54 %	$ 1.75 B	USA
Sol-Gel Technologies Ltd. SLGL	496 K	$ 69.37	0.35 %	$ 193 M	Israel
UroGen Pharma Ltd. URGN	122 M	$ 43.82	0.02 %	$ 2.11 B	Israel
United Therapeutics Corporation UTHR	600 M	$ 497.97	2.12 %	$ 22.1 B	USA
Spero Therapeutics SPRO	939 K	$ 1.19	0.41 %	$ 66.7 M	USA
Scholar Rock Holding Corporation SRRK	99.7 M	$ 57.42	3.78 %	$ 6.59 B	USA
Jounce Therapeutics JNCE	5.87 M	-	-	$ 98.4 M	USA
NextCure NXTC	4.15 M	$ 8.42	7.67 %	$ 23.9 M	USA
Verrica Pharmaceuticals VRCA	31 M	$ 5.26	0.75 %	$ 56 M	USA
Viridian Therapeutics VRDN	1.9 M	$ 23.17	1.09 %	$ 2.36 B	USA
Zosano Pharma Corporation ZSAN	3.08 M	-	7.23 %	$ 2.72 M	USA
Vertex Pharmaceuticals Incorporated VRTX	107 M	$ 528.9	0.22 %	$ 135 B	USA
Verastem VSTM	40.7 M	$ 8.08	0.55 %	$ 560 M	USA
vTv Therapeutics VTVT	169 K	$ 32.79	0.03 %	$ 130 M	USA
Voyager Therapeutics VYGR	28.7 M	$ 3.4	3.85 %	$ 200 M	USA
Aravive ARAV	1.88 M	-	-13.39 %	$ 1.45 M	USA
Wave Life Sciences Ltd. WVE	9.4 M	$ 4.91	1.03 %	$ 828 M	Singapore
Tonix Pharmaceuticals Holding Corp. TNXP	1.18 M	$ 13.16	0.15 %	$ 112 M	USA
Xenetic Biosciences XBIO	213 K	$ 4.28	0.86 %	$ 7.28 M	USA
Exicure XCUR	5.21 M	$ 1.41	12.8 %	$ 8.88 M	USA
Xenon Pharmaceuticals XENE	6.41 M	$ 59.55	0.18 %	$ 4.72 B	Canada
Xeris Pharmaceuticals XERS	220 M	$ 8.48	0.12 %	$ 1.36 B	USA